New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe ...

AR = Androgen receptor; ER = Estrogen receptor; GR = Glucocorticoid receptor; MR = Mineralocorticoid receptor; PR = Progesterone receptor. The relative binding affinity (%) of the main progestins ...

AR = Androgen receptor; ER = Estrogen receptor; GR = Glucocorticoid receptor; MR = Mineralocorticoid receptor; PR = Progesterone receptor. The relative binding affinity (%) of the main progestins ...

Berlin: Bayer has announced the submission of marketing authorization applications to the U.S. Food and Drug Administration ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

The Danish group bought rights to ocedurenone, an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA), from the Singapore biotech in October 2023 as a companion to its GLP-1-based ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

Intensive blood pressure control in hypertensive chronic kidney disease (CKD) provides a survival advantage and other benefits.

The orally-active drug, a non-steroidal mineralocorticoid receptor antagonist (nsMRA), is currently in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension – in other words ...

This is important because at higher levels, cortisol may also bind to mineralocorticoid receptors. This may explain why many synthetic glucocorticoids have mineralocorticoid activity [2].

Depression refers to a state of low mood that can be accompanied with loss of interest in activities that the individual normally perceived as pleasurable, altered appetite and sleep/wake balance ...